Allergy Therapeutics plc (AIM:AGY)
London · Delayed Price · Currency is GBP · Price in GBX 5.40
-0.58 (-9.70%)
Jul 27, 2026, 4:35 PM GMT
Allergy Therapeutics Cash Flow Statement
Financials in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Income | -47.17 | -39.2 | -39.17 | -41.77 | -12.66 | 3.66 |
Depreciation & Amortization | 4.4 | 4.17 | 4.32 | 4.22 | 4.17 | 4.13 |
Stock-Based Compensation | 1.96 | 0.87 | 0.76 | 0.11 | 0.47 | 0.64 |
Other Adjustments | 12.77 | 9.95 | 2.41 | 0.98 | 0.12 | -1.45 |
Change in Receivables | -1.8 | 0.27 | 0.14 | 3.38 | -4.25 | 2.14 |
Changes in Inventories | -1.5 | -1.02 | -1.24 | -0.18 | -0.57 | -1.12 |
Changes in Accounts Payable | -1.07 | -2.58 | 0.79 | 4.82 | -1.07 | 0.55 |
Changes in Income Taxes Payable | 0.77 | -0.57 | -0.15 | -0.45 | -0.21 | 0.04 |
Operating Cash Flow | -32.16 | -28.11 | -32.14 | -28.88 | -14 | 8.59 |
Operating Cash Flow Growth | - | - | - | - | - | -31.20% |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Capital Expenditures | -4.55 | -3.26 | -3.4 | -4.67 | -3.06 | -2.56 |
Purchases of Intangible Assets | -0.09 | -0.16 | - | - | - | - |
Proceeds from Sale of Investments | - | 0.27 | 2.07 | - | - | - |
Other Investing Activities | 0.24 | 0.27 | 0.14 | 0.08 | 0.06 | -0.08 |
Investing Cash Flow | -4.22 | -2.89 | -1.2 | -4.59 | -3 | -2.64 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Long-Term Debt Issued | 29.12 | 40.31 | 37.09 | 36 | - | 0.63 |
Long-Term Debt Repaid | -2.41 | -7.27 | -4.52 | -11.53 | -2.27 | -2.36 |
Net Long-Term Debt Issued (Repaid) | 26.71 | 33.05 | 32.57 | 24.47 | -2.27 | -1.74 |
Issuance of Common Stock | 1.36 | - | 1.36 | 6.49 | 0 | 0 |
Net Common Stock Issued (Repurchased) | 1.36 | - | 1.36 | 6.49 | 0 | 0 |
Other Financing Activities | -1.23 | -1.88 | -2.5 | -3.16 | -0.54 | -0.49 |
Financing Cash Flow | 25.49 | 31.16 | 31.43 | 27.8 | -2.81 | -2.22 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Foreign Exchange Rate Adjustments | -0.34 | -0.29 | -0.02 | 0 | 0.05 | -0.42 |
Net Cash Flow | -11.25 | 0.17 | -1.91 | -5.67 | -19.81 | 3.73 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Free Cash Flow | -36.71 | -31.37 | -35.54 | -33.55 | -17.06 | 6.03 |
Free Cash Flow Growth | - | - | - | - | - | -41.03% |
FCF Margin | -64.07% | -57.00% | -64.38% | -56.30% | -23.44% | 7.15% |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.05 | -0.03 | 0.01 |
Levered Free Cash Flow | -24.21 | -10.35 | -5.73 | -14.86 | -16.79 | 2.19 |
Unlevered Free Cash Flow | -34.05 | -32.09 | -34.45 | -37.15 | -14.07 | 4.22 |